Washington State University researchers find critical link for melanomaJuly 10, 2018A critical link in mapping recurrent mutations of melanoma has been discovered by researchers at Washington State University (WSU) School of Molecular Biosciences (SMB), a part of the university's College of Veterinary Medicine. The study, which was conducted in collaboration with researchers at Georgia State University, could lead to a better understanding of which mutations are important for causing skin cancer in humans and potentially identify new drug targets for treatment. In a paper published last week in "Nature Communications," the research team established that DNA binding by a specific set of transcription factors, called ETS, is inherently mutagenic in UV-exposed cells. With new genome mapping technology, these findings provide a crucial understanding of mutations that result at ETS binding sites located in specific genes that are known to be drivers in the onset of melanoma in humans. Using a WSU-established sequencing-based technology that allows the mapping of the locations of UV-induced DNA damage throughout the whole human genome, researchers generated a high-resolution UV damage map in human cells. By correlating the UV damage map with melanoma mutations, they discovered significantly elevated UV damage levels at ETS binding sites, which significantly increased mutation rates at the same sites in …
SPONSORED CONTENTSee what precise nutrition can do.Get to the bottom of tough gastrointestinal cases and recommend diets precisely designed to meet your patients' unique needs. + Find out more
Auburn Oncology Service launches melanoma drug clinical trialApril 5, 2018The Oncology Service at Auburn University's College of Veterinary Medicine is using the help of man's best friend in launching a clinical trial to test a new melanoma treatment drug. "This study is designed to test a new drug that may be useful in treating melanoma, which most commonly occurs in the mouth in dogs," said Bruce Smith, VMD, Ph.D., a professor in the Department of Pathobiology and director of the Auburn University Research Initiative in Cancer, or AURIC. "The drug, called MMX, is a peptide, which is a chain of amino acids, the basic building blocks of all proteins," Dr. Smith said. "This study seeks to measure the effect of this drug on these tumors. We are currently taking patients to participate in the clinical trial." Dog owners who are interested in enrolling their pets into this clinical trial must do so through the Oncology Service at the college's Wilford and Kate Bailey Small Animal Teaching Hospital. The treatment, as well as surgery to remove any tumor left at the end of the trial, will be provided at no cost to the owner. The trial initially is about a five-week …
